AUTHORS
Marc S. Hoffmann, MD, Grzegorz S. Nowakowski?2, Michal Kwiatek, MD, PhD3, Maria Bouzani, MD, PhD4, Dagmara Zimowska-Curylo5, Muhamad Alhaj Moustafa, MD, MS6, Alejandro Martín García-Sancho, MD, PhD7, Juan-Manuel Sancho, MD PhD8, Wojciech Jurczak, MD, PhD9, Floriane Boucaud10, Tomi Fakolade11, Mark Kaplan, PhD12, Arnaud Amzallag13, Matthew E. Stokes14, Tanvi Jindia15, Serena Perna, MD16, Theodoros Vassilakopoulos17
AFFILIATIONS
1 The University of Kansas Cancer Center, Kansas City, Kansas, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 AidPort Clinical Trials Hospital, Skórzewo, Poland
4 Evangelismos General Hospital, Athens, Greece
5 Krakow University, Krakow, Poland
6 Mayo Clinic, Rochester, Minnesota, United States
7 University of Salamanca, Salamanca, Spain
8 Institut Català d'Oncologia (ICO), Barcelona, Spain
9 Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland
10 Bristol Myers Squibb, Boudry, Switzerland
11 Bristol Myers Squibb, Boudry, Switzerland
12 Bristol Myers Squibb, Madison, United States
13 Bristol Myers Squibb, Cambridge, Massachusetts, United States
14 Bristol Myers Squibb, Madison, United States
15 Bristol Myers Squibb, Hyderabad, India
16 Bristol Myers Squibb, Madison, United States
17 National and Kapodistrian University of Athens, Athens, Greece
ABSTRACT
Background:
Approximately 40% of pts with diffuse large B-cell lymphoma (DLBCL) will relapse or have refractory disease following first-line (1L) treatment (Tx) with standard-of-care (SOC) chemoimmunotherapy regimens R-CHOP or Pola-R-CHP. Populations at high risk (HR) for relapse include those with International Prognostic Index (IPI) score 3–5 or IPI 1–2 with either ≥ 1 lesion ≥ 7 cm or baseline lactate dehydrogenase > 1.3 × ULN (Maurer et al, ASH 2023, #4512).
GOLCA is a potential, first-in-class, oral CELMoD designed for the Tx of lymphoma, with preferential distribution to lymphoid organs and enhanced activity in lymphoma cell lines. GOLCA drives the closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos, leading to direct cell killing (agnostic of cell of origin [COO]) and immunomodulatory activity.
CC-220-DLBCL-001 (NCT04884035) is an ongoing phase (Ph) 1b, open-label, multicenter trial to assess safety and preliminary efficacy of GOLCA + R-CHOP and GOLCA + Pola-R-CHP in pts with newly diagnosed a-BCL. GOLCA + R-CHOP demonstrated a manageable safety profile and encouraging efficacy with high complete metabolic response (CMR) rate (88%) at end of Tx (EOT), minimal residual disease (MRD ≥ 90%) negativity rates, and 24-month progression-free survival (PFS; 79%) (Nowakowski et al, ASH 2025, #476) and is being evaluated in the Ph 3 study GOLSEEK-1 (NCT06356129). We report updated efficacy results with extended median follow-up (f/u) of 24 months, including 24-month PFS and overall survival (OS) rates with GOLCA + Pola-R-CHP.
Methods:
Pts aged ≥ 18 y with Eastern Cooperative Oncology Group performance status ≤ 2, IPI 0–5 (Part 2A) or 2–5 (Part 2B), and newly diagnosed a-BCL with measurable disease were included. Pts were treated with GOLCA + Pola-R-CHP for six 21-day (D) cycles or until disease progression/unacceptable toxicity/study withdrawal. In dose escalation, GOLCA was dosed at 0.2 or 0.4 mg D1–7. In dose expansion, pts were randomized 1:1 to Pola-R-CHP + GOLCA 0.2 or 0.4 mg. Primary endpoint was safety; secondary endpoints included overall response rate (ORR), CMR rate at EOT, duration of response (DOR), PFS, and OS.
Results:
At data cutoff (30 May 2026), 57 pts were treated with GOLCA + Pola-R-CHP (0.2 mg, n=28; 0.4 mg, n=29). Median age was 63 y. Most pts had HR disease (86%) and DLBCL not otherwise specified histology (84%). COO was germinal center B cell (GCB) in 47% of pts and non-GCB in 39% of pts by Hans algorithm. Forty-seven pts (83%) completed Tx and 52 (91%) entered the f/u period.
At 24.1-month median f/u, EOT CMR rate (including durable computer tomography–based complete responses) was 69% (n=18) at 0.2 mg, 89% (n=25) at 0.4 mg (all 25 pts were alive and progression free at data cutoff), and similar across COO subtypes. EOT CMR was consistent in HR pts (65% [n=15] at 0.2 mg; 88% [n=21] at 0.4 mg). The 18-month DOR rate was 83% at 0.2 mg and 96% at 0.4 mg. The 24-month PFS rate at 0.4 mg was 96% and 95% in the overall and HR populations, respectively. The 24-month OS at 0.4 mg was 100% in both overall and HR pts.
In pts with both pre-Tx and EOT ctDNA analysis, 65% and 83% at 0.2 and 0.4 mg, respectively, achieved MRD negativity (undetectable MRD by PhasED-Seq) at EOT.
The safety profile was consistent with the previous report, with no new safety signals, and treatment emergent adverse events (TEAEs) were mainly hematologic. Grade 3/4 TEAEs occurred in 95% of pts, most frequently neutropenia (86%), an expected on-target and reversible effect of GOLCA, and anemia (39%). Non-hematologic AEs (pneumonia, sepsis, fatigue, gastrointestinal disorders) were infrequent and mostly low grade. There were no Grade 5 AEs related to GOLCA. Median relative dose intensity for GOLCA and Pola-R-CHP components was >95%. GOLCA dose reductions were mostly due to neutropenia (5%), anemia (4%), and thrombocytopenia (4%).
Conclusions:
GOLCA + Pola-R-CHP demonstrated a predictable and manageable safety profile, and addition of GOLCA did not compromise median dose intensity of Pola-R-CHP. GOLCA 0.4 mg + Pola-R-CHP resulted in a high rate of CMRs that were durable, a high rate of MRD negativity, and a promising 24-month PFS rate. These data continue to show that?GOLCA + SOC regimens R-CHOP and Pola-R-CHP have the potential to improve outcomes in 1L HR a-BCL. These data support physician flexibility in chemotherapy backbone selection and reinforce GOLCA as a differentiated CELMoD in lymphoma.
DISCLOSURES
Marc S. Hoffmann, MD: Genmab - Honoraria; Genentech - Research Funding; ADC Therapeutics - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); BeOne Medicines, Ltd - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)